Our Team

Michael-D.-West-Ph.-D.

Michael D. West, Ph.D.

CHIEF EXECUTIVE OFFICER

Michael D. West, Ph.D., is the founder and CEO of AgeX Therapeutics, Inc. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular ageing.  He has focused his academic and business career on the application of developmental biology to age-related degenerative disease. He was the founder and first CEO of Geron Corporation (Nasdaq: GERN), and from 1992 to 1998, he held various positions, including CEO, Director, and Vice President. From 1998 to 2007, Dr West held positions as CEO, President, and Chief Scientific Officer at Advanced Cell Technology, Inc. (ACT), which was eventually acquired by Astellas Pharma, Inc. From 2007 to 2018, he was CEO/Co-CEO of BioTime, Inc. (NYSE American: BTX).

aubrey-de-grey-phd

Aubrey de Grey, Ph.D.

VP, NEW TECHNOLOGY DISCOVERY

Aubrey de Grey, Ph.D.,​ is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He received his BA in computer science and Ph.D. in biology from the University of Cambridge, UK. He is also Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging. He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities and companies in areas ranging from pharma to life insurance, and to the public. He now dedicates 30% of his time to AgeX.

Our Team

Michael-D.-West-Ph.-D.

Michael D. West, Ph.D.

CHIEF EXECUTIVE OFFICER

Michael D. West, Ph.D., is the founder and CEO of AgeX Therapeutics, Inc. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cellular ageing.  He has focused his academic and business career on the application of developmental biology to age-related degenerative disease. He was the founder and first CEO of Geron Corporation (Nasdaq: GERN), and from 1992 to 1998, he held various positions, including CEO, Director, and Vice President. From 1998 to 2007, Dr West held positions as CEO, President, and Chief Scientific Officer at Advanced Cell Technology, Inc. (ACT), which was eventually acquired by Astellas Pharma, Inc. From 2007 to 2018, he was CEO/Co-CEO of BioTime, Inc. (NYSE American: BTX).

aubrey-de-grey-phd

Aubrey de Grey, Ph.D.

VP, NEW TECHNOLOGY DISCOVERY

Aubrey de Grey, Ph.D.,​ is the Chief Science Officer of SENS Research Foundation, a California-based 501(c)(3) biomedical research charity that performs and funds laboratory research dedicated to combating the aging process. He received his BA in computer science and Ph.D. in biology from the University of Cambridge, UK. He is also Editor-in-Chief of Rejuvenation Research, the world’s highest-impact peer-reviewed journal focused on intervention in aging. He is a highly sought-after speaker who gives 40-50 invited talks per year at scientific conferences, universities and companies in areas ranging from pharma to life insurance, and to the public. He now dedicates 30% of his time to AgeX.

OLYMPUS DIGITAL CAMERA

Nafees Malik, M.D.

CHIEF OPERATING OFFICER

Nafees Malik, M.D., is Chief Operating Officer at AgeX Therapeutics. He is an M.D. with a Master’s degree from the University of Cambridge. His 15 year career has involved roles spanning clinical medicine, investment banking, biopharmaceutical companies, research and academic institutions, and strategy consulting. For many years now, he has focused on the strategic and commercial analysis of cell and gene therapies and regenerative medicines. He is also Head of Cell and Gene Therapy at Juvenescence.

Russell-Skibsted-MBA

Russell Skibsted, M.B.A.

CHIEF FINANCIAL OFFICER

Russell Skibsted, M.B.A., is a seasoned executive with over 25 years’ experience in finance, acquisitions, partnering, marketing and operations with companies ranging from start-ups to a Fortune 5. He has over 14 years CFO experience for life science technology companies, with more than 10 years in public life science companies. Russell is the CFO of BioTime, Inc. (NYSE American: BTX), has a degree in Economics from Claremont McKenna College and an MBA from Stanford Graduate School of Business.

Ivan-Labat-Ph.D.

Ivan Labat, Ph.D.

CHIEF INFORMATION OFFICER

Ivan Labat, Ph.D., is a veteran of research and development of genome informatics. Over the last 25 years, he has held several biotech industry leadership positions in design, development and implementation of the next-generation DNA sequencing methods, data analysis and curation. Ivan received his M.S. in Molecular Biology and Physiology as well as his Ph.D. in Molecular Biology from the University of Belgrade.

Hal-Sternberg-Ph.D.

Hal Sternberg, Ph.D.

VP, RESEARCH

Hal Sternberg, Ph.D., is Vice President of Research. Prior to joining AgeX, he was BioTime’s Vice President of Research for over 25 years and was one of the company’s co-founders. Before that, Dr. Sternberg held various positions at the University of California at Berkeley from 1982 to 1988, where he worked on Alzheimer’s Disease. Dr. Sternberg was instrumental in the development of the medical product Hextend, bringing it through regulatory approval as a blood plasma volume expander for treating blood loss. Dr. Sternberg received his M.S. in Chemistry (1979) and Ph.D. in Biochemistry (1982) from the University of Maryland.

Dana-for-site

Dana Larocca, Ph.D.

VP, DISCOVERY RESEARCH

Dana Larocca has over 20 years of leadership experience in Biotechnology. At ReCyte Therapeutics, she served as VP of Research and Development.  She was founder and CEO of Mandala Biosciences, LLC where she raised over $3M in non-dilutive funding. Dr. Larocca previously held joint positions at Advanced Cell Technology (Astellas) and Sanford Burnham Prebys Medical Discovery Institute. She has over 40 scientific publications and 25 patents. Dr. Larocca holds a Ph.D. in Molecular and Cellular Biology from the University of Southern California and a B.S. in Biology from Ithaca College. She did her post-doctoral training at Harvard University.

Judith-Segall

Judith Segall

CORPORATE SECRETARY

Judith Segall is our Corporate Secretary. Ms. Segall currently serves as the Vice President of Administration of BioTime, Inc. and served on BioTime’s Board of Directors from 1990 through 1994, and from 1995 to June 2016. She was a co-founder of BioTime in 1990.

OLYMPUS DIGITAL CAMERA

Nafees Malik, M.D.

CHIEF OPERATING OFFICER

Nafees Malik, M.D., is Chief Operating Officer at AgeX Therapeutics. He is an M.D. with a Master’s degree from the University of Cambridge. His 15 year career has involved roles spanning clinical medicine, investment banking, biopharmaceutical companies, research and academic institutions, and strategy consulting. For many years now, he has focused on the strategic and commercial analysis of cell and gene therapies and regenerative medicines. He is also Head of Cell and Gene Therapy at Juvenescence.

Russell-Skibsted-MBA

Russell Skibsted, M.B.A.

CHIEF FINANCIAL OFFICER

Russell Skibsted, M.B.A., is a seasoned executive with over 25 years’ experience in finance, acquisitions, partnering, marketing and operations with companies ranging from start-ups to a Fortune 5. He has over 14 years CFO experience for life science technology companies, with more than 10 years in public life science companies. Russell is the CFO of BioTime, Inc. (NYSE American: BTX), has a degree in Economics from Claremont McKenna College and an MBA from Stanford Graduate School of Business.

Ivan-Labat-Ph.D.

Ivan Labat, Ph.D.

CHIEF INFORMATION OFFICER

Ivan Labat, Ph.D., is a veteran of research and development of genome informatics. Over the last 25 years, he has held several biotech industry leadership positions in design, development and implementation of the next-generation DNA sequencing methods, data analysis and curation. Ivan received his M.S. in Molecular Biology and Physiology as well as his Ph.D. in Molecular Biology from the University of Belgrade.

Hal-Sternberg-Ph.D.

Hal Sternberg, Ph.D.

VP, RESEARCH

Hal Sternberg, Ph.D., is Vice President of Research. Prior to joining AgeX, he was BioTime’s Vice President of Research for over 25 years and was one of the company’s co-founders. Before that, Dr. Sternberg held various positions at the University of California at Berkeley from 1982 to 1988, where he worked on Alzheimer’s Disease. Dr. Sternberg was instrumental in the development of the medical product Hextend, bringing it through regulatory approval as a blood plasma volume expander for treating blood loss. Dr. Sternberg received his M.S. in Chemistry (1979) and Ph.D. in Biochemistry (1982) from the University of Maryland.

Dana-for-site

Dana Larocca, Ph.D.

VP, DISCOVERY RESEARCH

Dana Larocca has over 20 years of leadership experience in Biotechnology. At ReCyte Therapeutics, she served as VP of Research and Development.  She was founder and CEO of Mandala Biosciences, LLC where she raised over $3M in non-dilutive funding. Dr. Larocca previously held joint positions at Advanced Cell Technology (Astellas) and Sanford Burnham Prebys Medical Discovery Institute. She has over 40 scientific publications and 25 patents. Dr. Larocca holds a Ph.D. in Molecular and Cellular Biology from the University of Southern California and a B.S. in Biology from Ithaca College. She did her post-doctoral training at Harvard University.

Judith-Segall

Judith Segall

CORPORATE SECRETARY

Judith Segall is our Corporate Secretary. Ms. Segall currently serves as the Vice President of Administration of BioTime, Inc. and served on BioTime’s Board of Directors from 1990 through 1994, and from 1995 to June 2016. She was a co-founder of BioTime in 1990.

Board of Directors

Gregory Bailey, M.D.

Chairman of the Board

Gregory Bailey, M.D., is CEO of Juvenescence Limited, a company that develops therapeutics, so people can have healthier, longer lives.

Dr Bailey has been founding and financing life science companies since 1995. Some of these companies have traded on NASDAQ, AIM, AMEX and NYSE, reaching over $18 billion in market capitalization. He co-founded Ascent Health Care in 1995, which was sold to Stryker for $525 million in 2009. In 2004, he was the initial financier and a board member of Medivation, Inc. (MDVN: NASDAQ). It was ultimately acquired by Pfizer in September 2016 for $14.3 billion. In January 2014, Dr Bailey along with his partners capitalized Biohaven through Portage Biotech with $3.5 million, subsequently adding a further $3.5 million over the next two years. Biohaven went public May 2017 on NYSE. Portage was the major shareholder in Biohaven until it did a dividend of $210 million of Biohaven shares to Portage shareholders. Dr Bailey remains a major shareholder of Biohaven, which has a market cap of a little over $1.5 billion.

Along with AgeX, Gregory Bailey currently sits on the Board of Directors of three public companies: Portage Biotech, Inc. (PTGEF:OTC); SalvaRx PLC. (SALV.L:AIM); and Biohaven Pharmaceutical Holding Company Ltd. (BHVN:NYSE).

Dr Bailey received his medical doctorate from the University of Western Ontario.

Michael D. West, Ph.D.

Founder and CEO

Dr. West is Chief Executive Officer of AgeX Therapeutics, Inc. He received his Ph.D. from Baylor College of Medicine in 1989 concentrating on the biology of cell senescence.  He has focused his academic and business career on the application of developmental biology to age-related degenerative disease.

He was the founder and first CEO of Geron Corporation (Nasdaq: GERN) and from 1992 to 1998, he was variously, CEO, Director, and Vice President, where he initiated and managed programs in telomerase diagnostics, oligonucleotide-based telomerase inhibition as anti-tumor therapy, and the cloning and use of telomerase in telomerase-mediated therapy wherein telomerase is utilized to immortalize human cells. From 1995 to 1998, while at Geron he organized and managed the research collaboration between the company and its academic collaborators James Thomson and John Gearhart that led to the first isolation of human embryonic stem and human embryonic germ cells.

From 1998 to 2007, Dr West held positions as CEO, President, and Chief Scientific Officer at Advanced Cell Technology, Inc. (ACT), which was eventually acquired by Astellas Pharma, Inc. At ACT, he managed programs in reprogramming developmental aging using somatic cell nuclear transfer, retinal differentiation, and PureStem, a technology for the multiplex derivation and characterization of diverse clonal human embryonic progenitor cell lines.

From 2007 to 2018, he was CEO/Co-CEO of BioTime, Inc. (NYSE American: BTX), where he led BioTime’s efforts to acquire Geron’s stem cell assets, now residing in the BioTime subsidiary Asterias Biotherapeutics (NYSE American: AST); the development of OpRegen for age-related macular degeneration; Renevia, a matrix for lipotransfer; and diverse novel preclinical programs in orthopedics and other applications in regenerative medicine.

At AgeX Therapeutics, he currently leads preclinical-stage programs in metabolic and vascular aging as well as induced Tissue Regeneration (iTR).

Annalisa Jenkins, M.B.B.S., F.R.C.P.

Dr. Annalisa Jenkins is a life sciences thought leader with over 25 years of biopharmaceutical industry experience. Prior to evolving her professional portfolio of non-executive board roles and non-profit and academic appointments, Dr. Jenkins served as President and CEO of Dimension Therapeutics, a leading gene therapy company that was acquired by Ultragenyx in November 2017. Prior leadership roles have included Head of Global Research and Development and Executive Vice President of Global Development and Medical at Merck Serono, and several senior positions at Bristol Myers-Squibb over 15 years, including serving as Senior Vice President and Head of Global Medical Affairs.

Earlier in her career, Dr. Jenkins was a Medical Officer in the British Royal Navy during the Gulf Conflict, achieving the rank of Surgeon Lieutenant Commander. Dr. Jenkins is a board member of several growing companies, including Ardelyx, Inc., iOx Therapeutics Limited, Thrombolytic Strategies, Inc., PhESi, Oncimmune, AVROBIO, COMPASS Pathways, AOBiome, Sensyne Health, Cocoon Biotech Inc. (Non-Executive Chair), Cell Medica (Non-Executive Chair), and Vium, Inc. (Executive Chair). She also is a committee member of the Science Board to the U.S. Food & Drug Administration (FDA), is Chair of The Court The London School of Hygiene and Tropical Medicine, and a board member of MedCity. Dr Jenkins is active in fund raising and strategic consulting to a number of UK and globally focussed non-profits in healthcare and education that includes YouBelong Community, Beanstalk and The Sepsis Trust. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the University of London and subsequently trained in cardiovascular medicine in the U.K. National Health Service.

Michael H. Mulroy

Michael H. Mulroy currently serves as President and Chief Executive Officer of Asterias Biotherapeutics (NYSE MKT: AST). Prior to joining Asterias in June 2017, Mr. Mulroy served as a Senior Advisor to CamberView Partners, LLC, which assists companies in connection with investor engagement and complex corporate governance issues. Mr. Mulroy served until September 2014 as Executive Vice President – Strategic Affairs and General Counsel of the Autoimmune and Rare Diseases Business Unit of Mallinckrodt plc following its acquisition of Questcor Pharmaceuticals, Inc. in August 2014.

Mr. Mulroy was appointed Executive Vice President, Strategic Affairs and General Counsel and Corporate Secretary of Questcor in February 2014, having previously served as Chief Financial Officer, General Counsel and Corporate Secretary since 2011. From 2003 to 2011, Mr. Mulroy was with the law firm of Stradling Yocca Carlson & Rauth, where he served as a partner from 2004, representing Questcor and other publicly-traded companies. From 1997 to 2003, Mr. Mulroy was an investment banker at Citigroup and Merrill Lynch.

Mr. Mulroy currently serves on the Board of Directors of Asterias Biotherapeutics, Inc. and BioTime, Inc.

Mr. Mulroy earned his J.D. degree from the University of California, Los Angeles, and his B.A. (Economics) from the University of Chicago.

John F. Mauldin

John F. Mauldin is a financial writer, publisher, and New York Times bestselling-author. Mr. Mauldin appears regularly on CNBC, Yahoo Tech Ticker, and Bloomberg TV and is a regular contributor to publications including The Financial Times and The Daily Reckoning. Mr. Mauldin currently serves as the President of Millennium Wave Advisors, which he joined in 2004, and is a member of the Board of Directors of Ashford Inc. Since November 2014. Mr. Mauldin has also served as Chairman of Mauldin Economics, an investment newsletter and information publishing firm.

Mr. Mauldin previously served as a member of the Board of Directors of Galectin Therapeutics, Inc. from May 2011 to December 2017. Mr. Mauldin earned his Master of Divinity from Southwestern Baptist Theological Seminary and his B.A. from Rice University.